TP 235
| Title | Journal |
|---|---|
| Activation of the Nrf2-ARE pathway by the Alternaria alternata mycotoxins altertoxin I and II. | Archives of toxicology 20170101 |
| Generation of a New Model Rat: Nrf2 Knockout Rats Are Sensitive to Aflatoxin B1 Toxicity. | Toxicological sciences : an official journal of the Society of Toxicology 20160701 |
| Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium. | PloS one 20150101 |
| Genetic or pharmacologic activation of Nrf2 signaling fails to protect against aflatoxin genotoxicity in hypersensitive GSTA3 knockout mice. | Toxicological sciences : an official journal of the Society of Toxicology 20140601 |
| Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO. | PloS one 20140101 |
| Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. | Free radical biology & medicine 20120815 |
| Synthetic triterpenoids, CDDO-Imidazolide and CDDO-Ethyl amide, induce chondrogenesis. | Osteoarthritis and cartilage 20120501 |
| Pharmacological induction of heme oxygenase-1 by a triterpenoid protects neurons against ischemic injury. | Stroke 20120501 |
| Implementation of a high-throughput screen for identifying small molecules to activate the Keap1-Nrf2-ARE pathway. | PloS one 20120101 |
| Synthesis and biological evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent. | Bioorganic & medicinal chemistry letters 20110415 |
| CDDO-Im is a stimulator of megakaryocytic differentiation. | Leukemia research 20110401 |
| CDDO-Im, an antitumor molecule that also improves platetet production. | Leukemia research 20110401 |
| Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents. | Journal of medicinal chemistry 20110324 |
| The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. | Clinical & experimental metastasis 20110301 |
| Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. | PloS one 20110101 |
| Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. | PloS one 20110101 |
| Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. | The Journal of pharmacology and experimental therapeutics 20101001 |
| Synthetic triterpenoids target the Arp2/3 complex and inhibit branched actin polymerization. | The Journal of biological chemistry 20100903 |
| Synthetic triterpenoids inhibit growth, induce apoptosis and suppress pro-survival Akt, mTOR and NF-{kappa}B signaling proteins in colorectal cancer cells. | Anticancer research 20100301 |
| Active NF-E2-related factor (Nrf2) contributes to keep endothelial NO synthase (eNOS) in the coupled state: role of reactive oxygen species (ROS), eNOS, and heme oxygenase (HO-1) levels. | The Journal of biological chemistry 20091113 |
| The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice. | American journal of respiratory and critical care medicine 20091101 |
| Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. | European journal of pharmacology 20091012 |
| Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. | Proceedings of the National Academy of Sciences of the United States of America 20090929 |
| High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide. | Cancer letters 20090918 |
| Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. | Carcinogenesis 20090601 |
| CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. | Toxicology and applied pharmacology 20090401 |
| CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia. | Leukemia research 20081201 |
| Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity. | Toxicology and applied pharmacology 20080915 |
| A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. | Cancer research 20080815 |
| Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels. | Leukemia research 20080801 |
| Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. | Hepatology (Baltimore, Md.) 20080801 |
| Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. | Toxicological sciences : an official journal of the Society of Toxicology 20080701 |
| Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells. | Leukemia 20080601 |
| The synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cells. | Cancer investigation 20080301 |
| Immunomodulatory activity of synthetic triterpenoids: inhibition of lymphocyte proliferation, cell-mediated cytotoxicity, and cytokine gene expression through suppression of NF-kappaB. | Immunopharmacology and immunotoxicology 20080101 |
| Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. | Antioxidants & redox signaling 20071101 |
| Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling. | Journal of neuro-oncology 20070901 |
| Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents. | Journal of medicinal chemistry 20070419 |
| Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. | Molecular cancer therapeutics 20070101 |
| Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. | Biochemical and biophysical research communications 20061229 |
| The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. | Molecular cancer therapeutics 20061201 |
| The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060715 |
| The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. | Molecular cancer therapeutics 20060601 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060315 |
| Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. | Cancer research 20060215 |
| 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. | The Journal of biological chemistry 20051028 |
| The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. | Cancer research 20050601 |
| Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. | Cancer research 20050601 |
| Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells. | Cell death and differentiation 20050501 |
| Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. | Molecular cancer therapeutics 20041001 |
| The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. | Blood 20040415 |
| Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. | Molecular cancer therapeutics 20040101 |
| The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030701 |
| Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. | Cancer research 20030315 |
| A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. | Bioorganic & medicinal chemistry letters 20020408 |